Richard Driscoll 1950-2017
It is with great regret and sadness that we have to inform you of the untimely passing of our friend and colleague Richard Driscoll. Richard passed away on the morning of Saturday 21st October, following a cardiac arrest last week. He is survived by his wife Aviva, sons Adam, Sam and Jonny, and by three grandchildren. They and his wider family, friends and colleagues have our sincerest condolences.
Many people associated with the IBD Registry will have met or worked with Richard in his role as Development Lead. He was a significant driving force behind the Registry’s set up, and worked tirelessly to overcome the challenges involved, with grace and determination.
Richard was a hugely engaging, warm and insightful individual. His impact on patients with Inflammatory Bowel Disease has been enormous, and will continue to be felt for years to come. Most of all, Richard was a kind and generous person, who placed his family, community, friends and colleagues before anything. I’m sure many of us have very positive memories of any interaction with Richard, be it large or small. He will be sorely missed.
IBD Registry Chair
IBD Registry Clinical Lead
The UK IBD Registry
The IBD Registry is the vehicle for the biologics audit and quality improvement programme. Teams can participate using a choice of data entry systems including existing local systems. Being part of the Registry will give teams:
- Local data to manage their biologics patients and IBD service more effectively
- The chance to be part of a national audit of the safety and appropriate use of biologics and biosimilars
The Registry has the potential to become a unique resource for real-world clinical effectiveness and health economic studies in IBD care. While data can be collected on all IBD treatments, the focus for 2016/17 is on biologics. The aims are to:
- Transfer data collection to the IBD Registry from the RCP biological therapy audit web tool, which has now closed
- Develop a near-complete UK Register of IBD patients on biologics by the end of 2017
Find out more about…